A single daily dose of maropitant was more effective than metoclopramide administered two or three times daily in the treatment of emesis caused by various aetiologies in dogs.

Maropitant is a neurokinin-1 inhibitor that acts to prevent and treat vomiting by blocking stimuli to the final common pathway in the emetic centre of the brain. The field efficacy and safety of a single oral dose of maropitant were investigated for the prevention of vomiting in dogs with a history of motion sickness resulting from transportation by car in two blinded, placebo-controlled studies. In an exploratory study designed as a two-way crossover trial with 17 dogs, 10 of the dogs given the placebo vomited during a car journey but only three of the dogs vomited under maropitant treatment. In a larger multicentred parallel design study, 69 of 105 dogs treated with the placebo vomited during the journey compared with 15 of 106 dogs treated with maropitant (P < 0.0001).

No abstract

This communication reports incidental observations on Toxascaris leonina infections in a beagle breeding colony. Regular faecal monitoring demonstrated that T. leonina was endemic in the adult dam population within this colony. Small numbers of T. leonina eggs were also detected in the faeces of weaned pups from eight weeks of age possibly produced by a patent infection. This would mean a pre-patent period for T. leonina of 56 days or less. Worm counts on 10 pups showed that 60% of pups had acquired a T. leonina infection by 12 weeks of age. Since prenatal and lactogenic transmission do not occur and as the pups were kept in an environment which reduced chances of infection with T. leonina and there was no apparent source of paratenic hosts, the source of infection must have been embryonated T. leonina eggs from the whelping environment. These observations on T. leonina demonstrate that, if pups are exposed to an infected environment, patent infections may be seen in a younger age group than is normally associated with T. leonina infections.